Atara Biotherapeutics, Inc. (ATRA) SEC Filings

Atara Biotherapeutics, Inc. (ATRA) is named as the issuer in a Form 144 filed on behalf of employee Nguyen AnhCo, indicating an intent to sell 5,062 shares of common stock through Morgan Stanley Smith Barney. The notice ties the shares to vested RSUs issued under an S-8 equity plan, with a portion sold automatically to satisfy tax withholding obligations under a sale-to-cover provision. The filing also reports a prior sale of shares within the last three months.

Atara Biotherapeutics, Inc. (ATRA) reported that President and CEO Nguyen AnhCo had 5,062 shares of common stock sold on August 17, 2026. According to the disclosure, these shares were sold automatically to satisfy tax withholding obligations upon vesting of restricted stock units under a sale-to-cover provision, at a broker-executed weighted average price. Following this transaction, Nguyen AnhCo directly holds 132,775 shares of Atara common stock.

Atara Biotherapeutics, Inc. is reported to have 7.6% of its common stock beneficially owned through entities related to Point72. As of the close of business on June 30, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen report beneficial ownership of 687,718 shares of common stock, with 0 shares under sole voting or dispositive power and 687,718 shares under shared voting and dispositive power. The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, and Point72 Associates has the right to receive dividends and sale proceeds for more than 5% of Atara’s outstanding common stock. The reporting persons expressly state that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.

Atara Biotherapeutics, Inc. reported second‑quarter 2026 commercialization revenue of $0.6 million, down sharply from $17.6 million a year earlier, primarily reflecting the prior‑year recognition of large Pierre Fabre milestone and service amounts. For the six months, revenue was $1.1 million versus $115.7 million in the prior‑year period.

The company posted a Q2 2026 net loss of $4.8 million and a six‑month net loss of $9.0 million, compared with net income of $2.4 million and $40.4 million in the respective 2025 periods. Operating expenses fell substantially as development, manufacturing, clinical and regulatory responsibilities for tab‑cel (Ebvallo) were transitioned to partner Pierre Fabre, which now funds these activities worldwide.

At June 30, 2026, Atara had $3.2 million in cash and cash equivalents and $6.7 million in short‑term investments, total assets of $21.0 million, total liabilities of $58.0 million, and a stockholders’ deficit of $37.0 million. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months, citing limited liquidity and the need for additional financing or strategic transactions. The company continues to earn commercialization revenue and retains rights to significant potential regulatory and commercial milestones and double‑digit tiered royalties on future global tab‑cel sales, though many of these payments are shared with HCRx under a sale‑of‑future‑revenues arrangement.

Atara Biotherapeutics reported second quarter 2026 results, highlighting major cost reductions and a return to losses after a one-time revenue boost in 2025. Commercialization revenue was $0.6 million versus $17.6 million a year earlier, largely because deferred revenue was accelerated in 2025 after transferring development activities to Pierre Fabre Laboratories, leaving less to recognize in 2026. Total costs and operating expenses fell sharply to $5.4 million from $14.4 million, reflecting an 87% year-over-year reduction in costs and operating expenses and substantially lower stock-based compensation.

Atara posted a net loss of $4.8 million, or ($0.32) per share, compared with net income of $2.4 million in the prior-year quarter. Cash, cash equivalents and short-term investments were $9.9 million as of June 30, 2026, slightly above March 31, 2026. The company expects this liquidity, together with realized operating efficiencies, to fund planned operations into mid-2027. Strategically, Atara and partner Pierre Fabre had a productive FDA Type A meeting on tabelecleucel (tab-cel), are preparing a BLA resubmission using updated ALLELE trial data, and Atara is eligible for a $31 million milestone upon potential FDA approval plus double-digit tiered royalties on EBVALLO sales.

Funds managed by Redmile Group, LLC exercised Atara Biotherapeutics pre-funded warrants on July 22, 2026 via a cashless exercise. The exercise delivered 195,211 shares of common stock to the funds, with 60 shares withheld to cover the exercise price. The funds continue to hold pre-funded warrants with low exercise prices ($0.0025 and $0.0001 per share), each limited by a 9.99% beneficial ownership blocker. Redmile and Jeremy Green report these as indirect holdings, disclaiming beneficial ownership beyond their pecuniary interest, and also correct prior warrant terms previously reported.

Atara Biotherapeutics, Inc. is the subject of an amended Schedule 13D/A filed by Redmile Group, LLC and related entities, updating their ownership after a warrant exercise. The reporting group may be deemed to beneficially own 950,994 shares of Atara common stock, representing 9.9% of the outstanding class.

The position consists of 636,852 shares held by Redmile-managed funds plus 314,142 shares issuable upon exercise of pre-funded warrants, capped by a 9.99% Beneficial Ownership Limitation. On July 16, 2026, Redmile effected a cashless exercise of certain warrants, leading to the issuance of 174,247 shares to Redmile Biopharma Investments II, L.P. and 20,904 shares to Redmile Strategic Long Only Trading Sub, Ltd., with small share amounts withheld to cover the exercise price. Redmile Strategic Long Only Trading Sub, Ltd. is reported to have ceased being a 5% beneficial owner on July 22, 2026.

Atara Biotherapeutics, Inc. reported that Kevin G. Sarney, serving as Interim CFO, filed an initial Form 3 statement of beneficial ownership. The filing lists him as an officer but shows no reported transactions or holdings details in the provided data.

Atara Biotherapeutics, Inc. reported leadership changes in its finance organization. The company notified Chief Accounting Officer Yanina Grant-Huerta that her employment will end effective July 17, 2026. This affects oversight of financial reporting and accounting.

Effective June 26, 2026, the board appointed Kevin G. Sarney of Charles River CFO, Inc. as interim chief financial officer. He will also serve as principal financial officer and principal accounting officer under a consulting agreement with CRCFO, which can be terminated by either party with 30 days’ written notice. Mr. Sarney brings over 25 years of life science finance and accounting experience and will enter into Atara’s standard indemnification agreement for executive officers.